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The  host  interferon  (IFN)  response  represents  one  of  the  ﬁrst  barriers that  inﬂuenza  viruses  must  sur-
mount  in  order  to  establish  an  infection.  Many  advances  have  been  made  in  recent  years  in understanding
the  interactions  between  inﬂuenza  viruses  and the  interferon  system.  In  this  review,  we  summarise  recent
work  regarding  activation  of  the  type  I  IFN  response  by  inﬂuenza  viruses,  including  attempts  to  identify
the  viral  RNA  responsible  for IFN  induction,  the  stage  of  the  virus  life  cycle  at which  it is generated  and
the  role  of defective  viruses  in  this  process.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
The inﬂuenza viruses are a leading cause of respiratory illness
in humans and are responsible for annual seasonal outbreaks that
have serious economic impact. In addition, the wide host range
of the virus and the potential for genome reassortment between
human inﬂuenza viruses and those of other species mean these
viruses present a pandemic threat. To establish a productive infec-
tion and thus cause disease, inﬂuenza viruses must overcome host
innate immune responses that are very rapidly activated during
infections. The interferon (IFN) family of antiviral cytokines play
a major role in these responses and are critical in restricting the
early stages of virus infections prior to the activation of the adaptive
immune system. The IFNs and other innate immune mediators have
serious implications for the outcome of inﬂuenza virus infections in
terms of disease severity, since highly pathogenic viruses are often
associated with excessive cytokine responses (Baskin et al., 2009;
Kash et al., 2006). In this review, we summarise recent develop-
ments in our understanding of how inﬂuenza viruses activate the
IFN system and highlight areas in which this understanding is still
incomplete.
2. The interferon response to inﬂuenza virus
The IFNs are expressed and secreted following the detection of
viral components within infected cells; subsequent binding of IFN
to its cognate receptor at cell surfaces leads to the upregulation
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of hundreds of different interferon-stimulated genes (ISGs) that
establish an ‘antiviral state’ to efﬁciently limit further replication
and spread of the virus (reviewed in Randall and Goodbourn, 2008).
Of these ISGs, several have been identiﬁed as having direct anti-
inﬂuenza virus activity. These include the Mx  family of GTPases,
which are thought to form oligomeric rings around viral nucle-
ocapsids to inhibit their nuclear import and/or replication (Gao
et al., 2011; Haller et al., 1980; Pavlovic et al., 1992; Turan et al.,
2004; Xiao et al., 2013; Zimmermann et al., 2011); viperin, which
affects virus budding and thus limits the release of viral particles
from infected cells (Wang et al., 2007) (although the contribution
of viperin to the restriction of inﬂuenza virus replication in vivo
is less clear-cut, Tan et al., 2012); and the IFN-induced trans-
membrane (IFITM) family members (in particular IFITM3), which
interfere with fusion between viral and endosomal membranes
thereby limiting viral entry (Brass et al., 2009; Desai et al., 2014;
Everitt et al., 2012; Feeley et al., 2011; Li et al., 2013).
The IFNs are classiﬁed into three types according to their amino
acid sequence and the type of receptor through which they sig-
nal. The type I IFNs (which include multiple IFN- subtypes and
IFN-) and the type III IFNs (IFN-) are directly upregulated fol-
lowing virus infection; these are the major IFNs secreted following
inﬂuenza virus infections in vitro and in vivo (Crotta et al., 2013;
Ioannidis et al., 2013; Jewell et al., 2010; Khaitov et al., 2009;
Wang et al., 2009). In contrast, type II IFN (IFN-) is secreted by
activated T lymphocytes and NK cells and will not be discussed
further in this review. Airway epithelial cells, plasmacytoid den-
dritic cells (pDCs) and macrophages are the main producers of
IFN during inﬂuenza virus infections (Cheung et al., 2002; Hogner
et al., 2013; Ioannidis et al., 2013; Jewell et al., 2007; Kallfass
et al., 2013; Kaminski et al., 2012). Several studies suggest that
airway epithelial cells are primarily responsible for type III IFN
http://dx.doi.org/10.1016/j.virusres.2015.02.003
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production while dendritic cells and alveolar macrophages are the
major source of type I IFNs (Ioannidis et al., 2013; Khaitov et al.,
2009; Wang et al., 2009). The induction of both type I and type III
IFNs in virus-infected epithelial cells is thought to occur in response
to the same viral ligands and via the same signalling components
(Crotta et al., 2013; Onoguchi et al., 2007); furthermore, the panel
of ISGs upregulated in airway epithelia in response to type I and
type III IFNs following inﬂuenza virus infection shows complete
overlap (Crotta et al., 2013). However, while the type I IFN receptor
is expressed at the surface of all cells, expression of the type III IFN
receptor is primarily restricted to epithelial cells in the respiratory
and gastrointestinal tracts (Mordstein et al., 2010; Sommereyns
et al., 2008). During an inﬂuenza virus infection, it is possible that
this differential expression of the type III IFN receptor functions to
elicit an antiviral response in airway epithelia while restricting the
activation of immune cells and associated lung pathology (Hogner
et al., 2013).
The IFN induction cascade becomes stimulated following the
recognition of certain molecular structures that are absent in
uninfected cells, termed pathogen-associated molecular patterns
(PAMPs). For RNA virus infections, these PAMPs are predominantly
certain features of viral RNA that are not usually present in cellu-
lar RNAs, such as regions of double-stranded RNA (dsRNA) or the
presence of a 5′-triphosphate (5′ppp) or a 5′-diphosphate (5′pp)
group. The pathogen-recognition receptors (PRRs) play a critical
role in the distinction of self from non-self molecules by binding to
PAMPs within infected cells. Two types of PRRs have been impli-
cated in the induction of IFNs by inﬂuenza viruses, with the role of
a particular PRR depending on the cell type and nature of the viral
stimuli. The Toll-like receptor (TLR) family of transmembrane pro-
teins are able to recognise a wide range of microbial ligands, and
signal downstream through either MyD88 (myeloid differentiation
primary response 88) or TRIF (Toll-interleukin-1 receptor (TIR)-
domain-containing adaptor inducing interferon (IFN)-)  adaptor
proteins to stimulate IFN expression, depending on the particular
TLR (reviewed in Lester and Li, 2014). TLR7 is a receptor for ssRNA
and recognises incoming virions in endosomal compartments dur-
ing inﬂuenza virus infection of pDCs (Diebold et al., 2004; Lund
et al., 2004); it is consequently required for the production of high
levels of type I IFNs by these cells (Diebold et al., 2004; Kaminski
et al., 2012; Lund et al., 2004). In other cell types, TLR7 is dispensable
for IFN induction by RNA viruses including inﬂuenza virus (Kato
et al., 2005; Koyama et al., 2007; Yoneyama et al., 2004), either
because it is not expressed (Mayer et al., 2007) or because its local-
isation is non-endosomal (Ioannidis et al., 2013). TLR3 recognises
dsRNA and is also activated by inﬂuenza virus infection (Le Gofﬁc
et al., 2007). However, although TLR3 contributes to IFN induction
by other viruses (reviewed in Lester and Li, 2014), TLR3-deﬁcient
airway epithelial cells and pDCs have normal type I IFN responses to
inﬂuenza virus infection (Diebold et al., 2004; Le Gofﬁc et al., 2007);
instead, TLR3 in the context of inﬂuenza virus infections functions
to activate pro-inﬂammatory signalling pathways (Guillot et al.,
2005; Le Gofﬁc et al., 2007).
Non-self RNAs in the cytoplasm are detected by a second group
of PRRs, the cytosolic RIG-I-like receptors (RLRs), consisting of RIG-
I, MDA-5 and LGP2. These receptors are essential for IFN induction
during RNA virus infections of non-pDC cell-types, and mice that
are deﬁcient in RLR signalling pathways are extremely suscepti-
ble to RNA viruses despite possessing intact TLR systems (Kato
et al., 2006; Kumar et al., 2006; Sun et al., 2006). Both RIG-I and
MDA-5 contain two caspase activation and recruitment domains
(CARDs) at their N-terminus, an RNA helicase domain possess-
ing dsRNA-dependent ATPase activity and a C-terminal regulatory
domain (CTD). Ligand binding to the CTD and the helicase domain
induces a conformational change in the RLRs that exposes the
CARDs (Kowalinski et al., 2011; Lu et al., 2010; Luo et al., 2011;
Wang et al., 2010). Activity following ligand binding is modulated
by the posttranslational modiﬁcation of the CARDs by dephos-
phorylation and/or ubiquitination (reviewed in Gack, 2014). For
example, TRIM25, RIPLET and/or MEX3C-dependent Lys63-linked
ubiquitination of the CARDs occurs following ligand binding to RIG-
I (Gack et al., 2007; Kuniyoshi et al., 2014; Oshiumi et al., 2009,
2010). Additionally, free Lys63 polyubiquitin chains have been
reported to bind RIG-I and MDA-5 CARDs and stimulate activity
(Zeng et al., 2010). Downstream signal transduction occurs by the
CARD-dependent association of RIG-I/MDA-5 with the mitochon-
drial antiviral signalling protein (MAVS) at the outer mitochondrial
membrane. This interaction promotes MAVS oligomerisation and
the assembly of large multiprotein complexes that activate NF-B
and the IFN regulatory factors (IRF3 or IRF7, depending on the IFN
subtype, Osterlund et al., 2007) to stimulate expression of type I
and type III IFNs. LGP2 has a similar structure to RIG-I and MDA-5
but lacks the CARDs; this protein has thus been implicated in the
regulation of RIG-I and MDA-5 activity (Childs et al., 2013; Saito
et al., 2007; Satoh et al., 2010).
RIG-I and MDA-5 each recognise different types of viral RNA,
with RIG-I most efﬁciently activated by short stretches of 5′ppp
or 5′pp dsRNA while MDA-5 is activated by longer stretches of
dsRNA in a 5′ phosphate-independent manner; these PRRs have
therefore been shown to recognise different families of RNA viruses
(Kato et al., 2006; Loo et al., 2008). Knockdown studies have
shown that IFN induction in response to inﬂuenza virus infection
is predominantly mediated through RIG-I (Kato et al., 2006; Loo
et al., 2008), and inﬂuenza virus-induced IFN expression in airway
epithelial cells, the primary site of inﬂuenza virus replication, is
RIG-I-dependent (Le Gofﬁc et al., 2007). MDA-5 may still contribute
to IFN induction by inﬂuenza viruses however, since small reduc-
tions in IFN induction and ISG responses can be seen in infected
MDA-5-deﬁcient cells compared to control cells (Husser et al.,
2011; Kato et al., 2006; Loo et al., 2008). Moreover, type I IFNs are
still produced following inﬂuenza virus infection or transfections
of inﬂuenza RNA in chicken cells, which lack RIG-I (Karpala et al.,
2011; Liniger et al., 2012). Instead, IFN induction in this system is
mediated through MDA-5 (Liniger et al., 2012).
3. Inﬂuenza virus replication
The inﬂuenza virus genome is composed of eight different seg-
ments of single-stranded negative-sense viral RNA (vRNA) that
exists in virions in the form of viral ribonucleoproteins (vRNPs)
which are the minimum units required for viral transcription and
replication (Shaw and Palese, 2013). vRNPs are held in a closed
circular conformation by the binding of the trimeric viral RNA-
dependent RNA polymerase to the partially complementary 5′ and
3′ termini of the vRNA, with the remainder of the vRNA seg-
ment bound along its length by viral nucleoprotein (NP) oligomers
(reviewed in Resa-Infante et al., 2011). Following binding of viri-
ons to sialic acid-containing receptors on the surface of host cells,
virus particles are taken into the cell by endocytosis followed by
vRNP release into the cytoplasm and import to the nucleus, where
they serve as the templates for viral transcription and replication.
vRNPs are ﬁrst transcribed by the vRNP-associated polymerase in
a reaction primed by 5′ capped 10–13nt RNAs that are derived
from cellular pre-mRNAs through the polymerase cap-binding and
endonucleolytic activities (reviewed in Fodor, 2013). Viral mRNA
synthesis is therefore dependent on the activity of host RNA poly-
merase II and can thus be inhibited by drugs that target cellular
transcription (Chan et al., 2006; Hay et al., 1977; Mark et al., 1979;
Vreede et al., 2011). The viral polymerase is also responsible for
polyadenylating the 3′ end of viral transcripts, following which
they are exported to the cytoplasm for viral protein expression.
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Replication of the inﬂuenza virus genome occurs through the
synthesis of full-length complementary copies of the vRNA, the
complementary RNA (cRNA). cRNAs are also encapsidated into
cRNPs, which in turn act as the template for the polymerase-
directed synthesis of progeny vRNPs. Since genome replication is
an unprimed reaction and occurs de novo, inﬂuenza virus vRNAs
and cRNAs possess a 5′ppp.
4. Evasion of PRR recognition by inﬂuenza viruses
If naked cRNAs and vRNAs were generated during the repli-
cation of the inﬂuenza virus genome, cRNA:vRNA hybridisation
would lead to the formation of RIG-I and MDA-5 ligands, activation
of the IFN response and restriction of virus replication. To avoid
this, inﬂuenza virus employs strategies to evade detection by RLRs,
thus allowing the virus to replicate efﬁciently without inducing
IFN. Firstly, unlike other RNA viruses that replicate exclusively
in the cytoplasm, inﬂuenza virus transcription and replication is
nuclear. Since RIG-I and MDA-5 are conﬁned to the cytoplasm,
nuclear genome replication means that cRNA and progeny vRNAs
are generated at a site that is inaccessible to these PRRs. Secondly,
the synthesis of full-length cRNA from vRNA and vice versa is very
closely coupled to encapsidation; the interaction between the ﬁrst
nucleoprotein monomer and polymerase at 5′ end of the RNA is
thought to nucleate the sequence-independent encapsidation of
the nascent RNA (Ye et al., 2006). Consequently, NP is required for
full-length genome ampliﬁcation (Honda et al., 1988; Mena et al.,
1999; Shapiro and Krug, 1988; Vreede et al., 2011). This process
also appears to involve cellular factors, since UAP56 and Tat-SF1
interact with NP to promote viral RNA encapsidation (Momose
et al., 2001; Naito et al., 2007). Thus, nascent full-length cRNA and
vRNA molecules do not exist as ‘free’ RNA and the formation of
cRNA:vRNA hybrids is prevented. Consistent with this, long dsRNAs
are undetectable during inﬂuenza virus infections (Bonin et al.,
2000; Kato et al., 2008; Pichlmair et al., 2006; Weber et al., 2006)
and the knockdown of UAP56 leads to an accumulation of dsRNA
in infected cells (Wisskirchen et al., 2011). Thirdly, inﬂuenza virus
encodes antagonists of the IFN system (reviewed in Garcia-Sastre,
2011). The principal of these is the NS1 protein, which targets multi-
ple components of the IFN induction cascade to limit IFN expression
(reviewed in Engel, 2013; Hale et al., 2008). NS1 sequesters dsRNA
to limit activation of RLRs (Donelan et al., 2003; Steidle et al.,
2010), targets TRIM25 to inhibit RIG-I activation (Gack et al., 2009)
and in some inﬂuenza virus strains, limits IFN expression post-
transcriptionally by interfering with the processing and nuclear
export of cellular mRNAs (Fortes et al., 1994; Hayman et al., 2006;
Nemeroff et al., 1998; Noah et al., 2003; Satterly et al., 2007). Other
viral proteins have also been described as having IFN-antagonistic
properties, including PB1-F2 (Dudek et al., 2011; Varga et al., 2011)
and the viral polymerase (Graef et al., 2010; Iwai et al., 2010; Vreede
et al., 2010). Nuclear replication, efﬁcient encapsidation of cRNA
and vRNA, and IFN antagonism by viral proteins are very effective
at preventing activation of the IFN system during infection: studies
examining IFN induction in individual cells infected with a range
of strains of inﬂuenza A virus found that the IFN- promoter had
only been activated in a small proportion of infected cells, both
in vitro and in vivo (Fig. 1) (Chen et al., 2010; Kallfass et al., 2013).
Furthermore, activation of the IFN response could not be detected
within some developing inﬂuenza virus plaques in lung epithelial
cells (Chen et al., 2010). This may  also be the case for inﬂuenza
viruses that do not express a functional NS1 protein and therefore
lack the principal viral IFN antagonist. Such viruses are known
to be better inducers of IFN than wild-type viruses (Egorov et al.,
1998; Garcia-Sastre et al., 1998; Kochs et al., 2009; Wang et al.,
2000), yet Kallfass et al. (2013) demonstrated IFN- promoter
activation in only a fraction of infected cells within the lung
epithelia of IFN- reporter mice infected with a virus lacking the
NS1 gene. Thus, the elevated IFN expression induced by this and
other NS1-defective viruses relative to wild-type virus is likely
to be due to a subset of infected cells (as has been observed for
cells infected with a paramyxovirus lacking an IFN antagonist,
Killip et al., 2011), and this is sufﬁcient for the establishment of
an antiviral state that impairs the replication of these viruses in
IFN-competent systems (Egorov et al., 1998; Garcia-Sastre et al.,
1998). The reasons for this cell-to-cell variation in IFN- promoter
activation by inﬂuenza are not yet fully resolved, but may  be
dictated by differences in the nature of the infecting virus particles
(i.e. the presence of defective interfering [DI] viruses, which will
be discussed later in this review, Baum et al., 2010; Chen et al.,
2010; Killip et al., 2011; Tapia et al., 2013), the host cell (Rand
et al., 2012; Zhao et al., 2012), or indeed a combination of both,
depending on the cell system and the virus used.
5. In vitro RIG-I ligands
Several different types of RNA have been identiﬁed as ligands
for RIG-I in the literature (reviewed in Schlee et al., 2009). The
presence of a triphosphate at the 5′ end of RNA is now generally
accepted as a particularly important characteristic in a RIG-I ligand
(Hornung et al., 2006; Kowalinski et al., 2011; Lu et al., 2010; Wang
et al., 2010), although it has been demonstrated recently that RIG-I
can additionally trigger IFN induction in response to RNA bear-
ing 5′-diphosphates (Goubau et al., 2014). Other features such as
double-strandedness, length and A/U composition can also deﬁne
the ability of RNA to induce IFN through RIG-I, irrespective of 5′
phosphates (Binder et al., 2011; Davis et al., 2012; Hausmann et al.,
2008; Kato et al., 2008; Malathi et al., 2007, 2010; Runge et al.,
2014; Saito et al., 2008; Uzri and Gehrke, 2009). Although early
studies suggested that in vitro transcribed 5′ppp single-stranded
RNA (ssRNA) could induce IFN through RIG-I (Hornung et al., 2006;
Kim et al., 2004), these results are now thought to be due to the
generation of unexpected basepaired RNA products in in vitro tran-
scription reactions, in addition to the expected ssRNA transcript
(Cazenave and Uhlenbeck, 1994; Schmidt et al., 2009). More recent
studies showed that there is a requirement for a region of blunt
dsRNA directly adjacent to the 5′ppp (Schlee et al., 2009; Schmidt
et al., 2009); these have since been backed up by structural studies
(Kolakofsky et al., 2012; Kowalinski et al., 2011; Lu et al., 2010).
The minimum length of the double-stranded region required to
give 5′ppp-dependent IFN induction has been shown to range from
10 basepairs (bp) (Kohlway et al., 2013; Schmidt et al., 2009) to at
least 19 bp (Schlee et al., 2009). Within this short dsRNA stretch,
there has been shown to be some tolerance of wobble base-pairs,
bulges and mismatches, as found in the ‘panhandle’ genome struc-
tures of single-stranded negative-sense RNA viruses (Marq et al.,
2011; Schlee et al., 2009). It is noteworthy that there are a number
of RNA structures, including 5′OH dsRNAs and 5′ppp dsRNAs with
overhanging nucleotides, that can bind to RIG-I yet do not stimulate
IFN induction (Hausmann et al., 2008; Lu et al., 2010; Marq et al.,
2011; Schmidt et al., 2009; Takahasi et al., 2008). Indeed, dsRNA
with a single overhanging 5′ppp nucleotide, such as those found
in some arenavirus genomes, can potently inhibit IFN- induction
by a blunt-ended 5′ppp dsRNA, presumably by competing with
blunt-ended 5′ppp dsRNA for RIG-I binding (Marq et al., 2011).
6. The inﬂuenza virus ‘panhandle’ as a RIG-I inducer
The 5′ and 3′ termini of the inﬂuenza virus genome segments
contain sequences of 13 and 12 nucleotides (nt) respectively that
are highly conserved across segments and virus subtypes (with
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Fig. 1. Heterogeneity in activation of the IFN induction cascade in cells infected with inﬂuenza viruses. A549 cells expressing GFP under the control of an IFN- promoter
(A549/pr(IFN-).GFP;  Chen et al., 2010) were infected with 5 PFU/cell of PR8, Udorn or WSN  strains of inﬂuenza A virus. Cells were left uninfected or infected with 5 PFU/cell
Sendai  virus (Cantell strain) as negative and positive controls for GFP expression respectively. At 16 h post-infection, monolayers ﬁxed and stained with antibody raised
against  disrupted X31 virus and DAPI; GFP (green), viral protein expression (red) and cell nuclei (blue) were subsequently examined by confocal microscopy.
the exception of a U4C variation in the 3′ terminus of some
genome segments) (Desselberger et al., 1980; Robertson, 1979).
These sequences possess a partial inverted complementarity, and
the inﬂuenza virus vRNA segments consequently have the potential
to form a ‘panhandle’ structure (Fig. 2A) that is believed to act as
the vRNA promoter (Fodor et al., 1994; Hsu et al., 1987; Tiley et al.,
1994). NMR, FRET and enzymatic studies of short naked RNAs corre-
sponding to the 3′ and 5′ termini have demonstrated the formation
of a stable partial duplex of approximately 15 bp in length between
the conserved termini and two to three additional segment-speciﬁc
bases, through Watson–Crick and non-Watson–Crick basepairing
(Fig. 2A) (Bae et al., 2001; Baudin et al., 1994; Cheong et al., 1996,
1999; Hsu et al., 1987; Noble et al., 2011; Tomescu et al., 2014).
Thus, the inﬂuenza virus panhandle has been suggested to be able to
act as a potent RIG-I ligand by virtue of the 5′ppp being directly adja-
cent to a small stretch of partially double-stranded RNA. Although
neither the formation of a panhandle structure within a full-length
genome segment nor the contribution of terminal base-pairing to
IFN induction by inﬂuenza virus have yet been directly demon-
strated, in vitro transcription products corresponding to inﬂuenza
virus segments are able to induce IFN when transfected into cells
(Baum et al., 2010; Osterlund et al., 2012) suggesting that the
inﬂuenza virus vRNAs possess an inherent ability to induce IFN.
The observations that RNA extracted from inﬂuenza virus-infected
cells, from puriﬁed inﬂuenza virions or from RNP reconstitutions
activate the IFN response when transfected into cells in a RIG-I-
dependent manner (Childs et al., 2012; Kato et al., 2008; Osterlund
et al., 2012; Pichlmair et al., 2006; Rehwinkel et al., 2010) have also
been used as evidence for IFN induction by the inﬂuenza panhan-
dle. IFN induction by RNA extracted from infected cells is unaffected
by RNase III treatment, which digests long dsRNAs into short frag-
ments of 12–15 bp (Kato et al., 2008). This may  be considered
Fig. 2. The panhandle and corkscrew structures of the inﬂuenza virus promoter. The panhandle (A) and corkscrew (B) conformations of inﬂuenza virus vRNA and the
corkscrew conformation of cRNA (C) are shown. Sequences shown from segment 5 (NP) of the WSN  strain of inﬂuenza virus.
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further support for IFN induction by the panhandle, since the base-
paired stem would presumably be too short in length to be targeted
by this enzyme.
While short free RNAs with the conserved 3′ and 5′ terminal
sequences of vRNA forms a panhandle structure (Bae et al., 2001;
Baudin et al., 1994; Cheong et al., 1996, 1999; Hsu et al., 1987; Noble
et al., 2011; Tomescu et al., 2014), evidence suggests that encap-
sidated polymerase-bound vRNA does not. Polymerase binding to
the vRNA termini causes the formation of a secondary structure, the
‘corkscrew’ conformation, which has been shown by several stud-
ies to be critical for viral polymerase activity (Brownlee and Sharps,
2002; Flick and Hobom, 1999; Flick et al., 1996; Leahy et al., 2001a,
2001b). In this structure, the very ends of the 5′ and 3′ termini do
not associate but instead form intra-termini hairpin loops (Fig. 2B)
(Flick et al., 1996). A highly sensitive single-molecule FRET assay
was recently used to examine changes in the structure of short
RNAs corresponding to the 5′ and 3′ termini of the genome seg-
ments. These RNAs form a partial dsRNA structure in the absence of
viral polymerase but undergo a polymerase-dependent conforma-
tional change that is consistent with the formation of the corkscrew
(Tomescu et al., 2014). The termini of free vRNA therefore form a
dsRNA panhandle that is recognised and bound with high afﬁnity
by the viral polymerase, causing the vRNA to adopt the corkscrew
conformation. Although the corkscrew permits some inter-strand
basepairing, this structure would be unlikely to activate RIG-I since
the terminal nucleotides do not bind each other to form dsRNA
(Flick and Hobom, 1999; Fodor et al., 1995). Furthermore, recent
structural determination of an inﬂuenza A virus polymerase in com-
plex with the vRNA promoter appears to be incompatible with RIG-I
binding of polymerase-associated RNA, since the 5′ppp end of the
vRNA is buried within the polymerase in a pocket formed by PA
and PB1 (Pﬂug et al., 2014). In order for an inﬂuenza virus genome
segment to activate RIG-I therefore, it is likely to exist in the pan-
handle conformation, which is suggestive of a free, unencapsidated
RNA.
The number of vRNA molecules within an infected cell vastly
outnumbers cRNA, with the proportion of vRNAs to cRNAs esti-
mated at between 10:1 and 40:1, depending on the segment
(Hatada et al., 1989; Mukaigawa et al., 1991). For this reason, much
of the work on inﬂuenza virus RNA and IFN induction has focused on
the vRNA. Given that the cRNA is an exact complement of the vRNA,
the cRNA termini are also partially complementary and would thus
be expected to form panhandle and corkscrew structures. Indeed,
cRNPs form closed helical loop structures similar to vRNPs (York
et al., 2013) and the formation of a corkscrew structure by the cRNA
termini has been demonstrated (Fig. 2C) (Azzeh et al., 2001; Crow
et al., 2004). It is possible that structural differences exist between
the vRNA and cRNA promoter structures however, since the wob-
ble basepairs at positions 3 and 5 in the vRNA promoter become
mismatched in the cRNA promoter; indeed, the structure of the
cRNA promoter has been suggested to be more unstable than that
of the vRNA (Park et al., 2003) so cRNA and vRNA may  differ in the
efﬁciency with which they activate RIG-I.
7. Identiﬁcation of natural inﬂuenza virus PAMPs
7.1. Identiﬁcation of RIG-I ligands from infected cells
Naked viral RNAs generated by in vitro transcription reactions or
by RNA extractions from infected cells have been shown to induce
IFN, yet such free RNAs would not be expected to be generated
during virus infections due to vRNA and cRNA encapsidation. Two
studies therefore addressed the nature of the ‘genuine’ viral PAMPs
responsible for activating RIG-I during inﬂuenza virus infections.
Baum et al. (2010) immunoprecipitated RIG-I from cells infected
with an NS1-deﬁcient virus, extracted RIG-I-associated RNA and
performed deep sequencing analyses to identify RIG-I ligands.
Although sequences mapping to all genome segments could be
detected in RIG-I immunoprecipitates, there was particular enrich-
ment for reads mapping to the smallest viral segments M and NS.
Furthermore, reads mapping to the PA and PB1 polymerase seg-
ments were particularly over-represented in the 5′ and 3′ regions,
which is highly suggestive of RNAs derived from genome segments
containing large internal deletions. This analysis did not determine
whether the RIG-I associated RNAs were vRNA, cRNA or mRNA in
nature, since the ampliﬁcation method used did not permit the
retention of strand orientation information.
Rehwinkel et al. (2010) used a different approach to address
the same question. The authors demonstrated the formation of
a trimolecular complex of RIG-I, an in vitro RNA transcript and
NS1, and by purifying this complex, RNA with IFN-inducing activity
could be isolated. A similar complex was postulated to form with
the bona ﬁde RIG-I agonist during inﬂuenza virus infection, per-
mitting genuine PAMPs from infected cells to be co-precipitated
with the NS1 protein. Consistent with this, RNA puriﬁed from NS1-
immunoprecipitates induced expression from an IFN- reporter
gene in a RIG-I- and 5′ppp-dependent manner, and NS1-associated
RNA was  enriched for full-length vRNA from all eight segments
(in addition to cRNA and mRNA from some segments). Further-
more, RIG-I immunoprecipitates also contained full-length vRNA
and cRNA, supporting the authors’ conclusions that full-length
genomes constitute the major PAMP in infected cells.
The identiﬁcation of inﬂuenza virus RNA, and in particular vRNA,
as ligands of RIG-I in these studies is not surprising, given that the
vRNA panhandle possesses the characteristics required for RIG-I
activation. What remains to be determined however is how the
vRNA panhandle structure is able to form in infected cells, since
replication of the virus genome is so closely coupled to encapsida-
tion of the nascent RNA. Two scenarios can be envisaged regarding
RIG-I activation during inﬂuenza virus infections. The ﬁrst is that
free vRNA, forming a panhandle, is generated erroneously at some
point in a virus infection; if this is the case, when and how is this
free RNA species generated? The second is that RIG-I can somehow
recognise vRNA within the context of a vRNP. Since the polymerase
obscures the genome termini, the latter of these scenarios would
presumably require displacement of the polymerase from the vRNA
promoter for RIG-I recognition. Interestingly, the individual poly-
merase subunits have been found to associate with RIG-I in an
RNA-independent manner (Li et al., 2014); although these asso-
ciations were not found to have clear implications for activation
of the IFN response, it is possible that RIG-I recruitment to the
vRNP through polymerase interactions could induce a conforma-
tional change in the vRNP structure that leads to formation and
exposure of the panhandle.
7.2. The requirements for transcription and replication
Since inﬂuenza viruses replicate in the nucleus and RIG-I resides
in the cytoplasm, incoming and progeny genomes traversing the
cytoplasm are the most obvious candidates for triggering IFN induc-
tion, and there is some debate about the contribution of each of
these to RIG-I activation by inﬂuenza viruses. Full-length genome
replication requires ongoing viral protein synthesis due to the
requirement for concurrent encapsidation by NP and newly syn-
thesised polymerase (Honda et al., 1988; Jorba et al., 2009; Shapiro
and Krug, 1988; Vreede et al., 2004; York et al., 2013); the transla-
tion inhibitor cycloheximide therefore prevents cRNP and progeny
vRNP accumulation (and subsequently secondary viral transcrip-
tion) in infected cells (Barrett et al., 1979; Hatada et al., 1989;
Vreede et al., 2004). Rehwinkel et al. (2010) reported that no RNA
capable of stimulating the IFN- promoter could be extracted from
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Fig. 3. Activation of the IFN induction cascade by inﬂuenza virus is sensitive to actinomycin D but not cycloheximide. A549 cells were infected with 5 PFU/cell of an NS1-
defective Udorn virus (Ud-99; Jackson et al., 2010) or a DI-rich preparation of PIV5 (PIV5-VC vM2; Killip et al., 2011), in the presence of 1 g/ml actinomycin D (ActD) or
50  g/ml cycloheximide (CHX) or were left untreated (UT). At 16 h post-infection, cell lysates were prepared and probed for phospho-IRF3 (p-IRF3), total IRF3, viral proteins
and  actin.
infected cells in the presence of cycloheximide. Furthermore, they
used an RNP reconstitution method to demonstrate IFN induc-
tion by reconstitutions with a transcription-defective but not a
replication-defective viral polymerase and thus concluded that
viral genome replication was required to stimulate IFN expression
(Rehwinkel et al., 2010). However, recent studies have demon-
strated IRF3 activation and transcription of both IFN- and ISG56
genes in conditions where progeny vRNA synthesis is inhibited,
either by cycloheximide treatment or using siRNA to NP (Fig. 3)
(Killip et al., 2014; Osterlund et al., 2012; Weber et al., 2013).
Incoming viral nucleocapsids have been implicated in RIG-I
activation by members of the Bunyaviridae, which also possess
segmented negative-sense RNA genomes with a 5′ppp panhandle
structure (Weber et al., 2013); activation of the IFN induction cas-
cade in the presence of cycloheximide would be consistent with
this also being the case for inﬂuenza virus infections. Indeed, a
recent study has reported the association of vRNPs with RIG-I
and MAVS at the mitochondrion at 3 h post-infection (Liedmann
et al., 2014). However, several studies have indicated that incom-
ing inﬂuenza A vRNPs are not sufﬁcient to induce IFN during
infection of epithelial cells and monocyte-derived DCs (moDCs),
and that viral RNA synthesis is required (Crotta et al., 2013;
Killip et al., 2014; Osterlund et al., 2012). Efﬁcient inhibition of
IRF3 and NF-kB activation by the cellular transcription inhibitors
actinomycin D and alpha-amanitin in inﬂuenza-infected cells
strongly suggests that incoming genomes do not function as a
major PAMP in lung epithelial cells (Fig. 3) (Killip et al., 2014).
These drugs do not affect the transport of incoming vRNPs to
the nucleus, but potently inhibit viral transcription (because of
the requirement for cellular transcripts for priming viral mRNA
synthesis) and cRNP and vRNP generation (due to inhibition
of de novo NP and polymerase synthesis). Virus-mediated IRF3
activation is also inhibited by 5,6-dichloro-1--d-ribofuranosyl-
benzimidazole (DRB) treatment (Killip et al., 2014), which permits
viral transcription but impedes the export of viral transcripts from
the nucleus (Amorim et al., 2007; Chan et al., 2006). The effects of
these drugs on IRF3 activation were speciﬁc to inﬂuenza viruses,
since they have no effect on activation of the IFN induction cascade
by the dsRNA analogue poly(I:C) or by paramyxoviruses (Fig. 3)
(Killip et al., 2014) which replicate in the cytoplasm and do not rely
on cellular transcription (Lamb and Parks, 2013). Moreover, expres-
sion of type I and type III IFNs following inﬂuenza A virus infection
correlates with the accumulation of viral RNAs (Osterlund et al.,
2012) and can be completely abrogated following inactivation of
the virus by heat or UV treatment (Crotta et al., 2013; Osterlund
et al., 2012). The above studies have been limited to a relatively
small number of inﬂuenza A virus strains, so it is conceivable that
different inﬂuenza A virus strains may  vary in their capacity to be
recognised by RIG-I during vRNP entry. Interestingly, inﬂuenza B
viruses elicit a much more rapid activation of IRF3 than inﬂuenza A
virus and this activation is insensitive to UV treatment (Osterlund
et al., 2012) indicating that the incoming genomes of these different
virus genera may  differ in their ability to be recognised by PRRs.
Taken together, these observations strongly suggest that the
generation of the major inﬂuenza A virus PAMPs requires the syn-
thesis and nuclear export of an RNA product or products from
incoming genomes, and that these RNAs can be generated even
in conditions where cRNP and vRNP accumulation is impaired.
Nevertheless, it is likely that distinct PAMPs are generated at dif-
ferent stages of the virus life cycle; thus, a minority of incoming
inﬂuenza A virus genomes may  contribute to IFN induction at
very early points post-infection, with viral polymerase products
(including, but not limited to, progeny genomes) functioning as a
more signiﬁcant PAMP population later in infection. The nature
of the PAMPs that are generated in the presence of cyclohex-
imide but not in the presence of cellular transcription inhibitors
has not yet been elucidated, and although the sensitivity of IRF3
activation to viral transcription inhibitors may superﬁcially sug-
gest that viral mRNAs can function as IFN inducers, the fact that
inﬂuenza virus mRNAs are 5′ capped and polyadenylated like host
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mRNAs makes this unlikely. Moreover, viral mRNAs cannot be
detected in RIG-I immunoprecipitations from infected cells, the
immunostimulatory activity of RIG-I associated RNA is sensitive
to calf intestinal phosphatase treatment (which removes 5′ phos-
phates), and RNA capable of inducing IFN is still generated in
RNP reconstitutions containing a transcription-defective viral poly-
merase (Rehwinkel et al., 2010). It is of note that actinomycin D
and alpha-amanitin can also affect the nucleocytoplasmic export
of viral mRNAs (Amorim et al., 2007; Killip et al., 2014; Mahy et al.,
1980) so may  also affect export of other viral RNA species; in actino-
mycin D and alpha-amanitin treatment conditions therefore, viral
PAMPs may  be retained in the nucleus and thus hidden from RIG-I.
It has been suggested that cRNA synthesis from input vRNP tem-
plates does not require viral protein synthesis for the initiation of
replication per se, but that de novo synthesised polymerase and
NP are required to stabilise the cRNA and prevent its degrada-
tion by host nucleases (Vreede et al., 2004, 2011). Unencapsidated,
unstable cRNAs would therefore be expected to be generated in
conditions where polymerase and NP synthesis has been blocked
by transcription or translation inhibitors, and these RNAs may  be
able to activate RIG-I if they were able to reach the cytoplasm.
7.3. Defective genomes and IFN induction by inﬂuenza virus
The observations that inﬂuenza viruses only activate the IFN
response in a fraction of infected cells with both wild-type and
NS1-defective viruses (Fig. 1) (Chen et al., 2010; Kallfass et al.,
2013) strongly suggest that activation of the IFN induction cascade
is not associated with ‘normal’ virus replication, which is perhaps
not surprising considering the nuclear localisation of replication
and the efﬁcient encapsidation of full-length genomes. The link
between the presence of ‘abnormal’ DI genomes and IFN induc-
tion by non-segmented negative-strand RNA viruses, including the
Paramyxoviridae and Rhabdoviridae, is well known. DI genomes
possess deletions that render a DI virus particle unable to com-
plete a full replication cycle due to the absence of the coding region
for one or more viral factor that is essential for replication; DI
viruses are therefore only able to replicate when a co-infecting non-
defective virus is present to supplement the missing viral factor/s.
Furthermore, DIs interfere with the multiplication of non-defective
virus by competing with non-DI genomes for replication and pack-
aging (reviewed in Marriott and Dimmock, 2010). Thus, although
DI genomes are considered non-infectious in terms of their inabil-
ity to generate viral progeny, they can still exert biological effects
in host cells. In particular, IFN induction by paramyxoviruses and
rhabdoviruses has been associated with ‘copyback’ or ‘snapback’
genome structures that are generated during template-switching
of the viral RNA-dependent RNA polymerase between strands of
opposite polarity (Baum et al., 2010; Johnston, 1981; Killip et al.,
2011, 2013; Marcus and Gaccione, 1989; Shingai et al., 2007; Strahle
et al., 2006). These structures possess often considerable stretches
of dsRNA adjacent to a 5′ppp and are thus very effective RIG-I lig-
ands (Baum et al., 2010; Strahle et al., 2007). Indeed, studies of
IFN induction in single cells infected with a paramyxovirus lack-
ing an IFN antagonist have indicated that the IFN- promoter is
not activated by the normal paramyxovirus life cycle, and that
only DI-rich virus preparations activated the IFN- promoter in a
majority of cells (Killip et al., 2011). It is as yet unclear whether
DI genomes themselves are responsible for inducing IFN, since
they are encapsidated into stable nucleocapsids (Strahle et al.,
2006) and should therefore be hidden from recognition by RIG-I.
DI-rich paramyxovirus preparations are potent activators of IRF3
even when progeny genome synthesis has been inhibited by cyclo-
heximide (Killip et al., 2012); however, unlike the situation for
inﬂuenza viruses, the requirements for RNA synthesis to IFN induc-
tion by paramyxovirus DI genomes cannot easily be studied using
inhibitors of cellular transcription, so it remains to be determined
whether input DI genomes are sufﬁcient for this process.
Inﬂuenza virus readily generates DI genomes; DI inﬂuenza
viruses were ﬁrst identiﬁed in the 1950s as ‘incomplete’ non-
infectious viruses that were selected for upon serial passage of
the virus in embryonated chicken eggs at high multiplicity (Von
Magnus, 1951a, 1951b) and they have been described in many stud-
ies since (reviewed in Dimmock and Easton, 2014; Nayak, 1980). In
contrast to non-segmented negative-strand RNA viruses, copyback
structures are not thought to be generated during inﬂuenza virus
replication. Instead, inﬂuenza DI viruses appear to be limited to
internal deletion RNAs that retain the 5′ and 3′ termini of genome
segment from which they are derived. Inﬂuenza virus DIs can arise
from all genome segments, but appear to be more readily detectable
from PB2, PB1 and PA segments. The generation of DIs  has long
been thought of as an artiﬁcial laboratory/tissue-culture artefact in
laboratory-prepared and egg-derived virus stocks, and their rel-
evance to genuine virus infections in vivo has been questioned.
However, several recent studies have suggested an important role
for DIs in natural inﬂuenza virus infections and in disease out-
come. Internal deletion DI viruses similar to those identiﬁed in vitro
have been detected in samples from infected mice (Tapia et al.,
2013), poultry (Jonges et al., 2014) and humans (Jonges et al., 2014;
Saira et al., 2013). Furthermore, DIs are generated de novo during
in vivo infections (Tapia et al., 2013) and the transmission of DI
viruses between human patients has been described (Saira et al.,
2013). Evidence is accumulating for an important role of inﬂuenza
virus DIs in IFN induction. Following a quantitative analysis of dif-
ferent subpopulations of an inﬂuenza virus, Marcus et al. (2005)
concluded that IFN-inducing particles are not productively infec-
tious. DI RNA was directly implicated in IFN induction by a study
that identiﬁed subgenomic RNAs derived from PA and PB1 seg-
ments in RIG-I immunoprecipitates from inﬂuenza virus-infected
cells (Baum et al., 2010). Subsequently, studies have correlated the
IFN-inducing phenotype of inﬂuenza viruses with a propensity to
generate or accumulate high numbers of DI genomes in tissue cul-
ture (Frensing et al., 2014; Ngunjiri et al., 2013; Perez-Cidoncha
et al., 2014). Perez-Cidoncha and colleagues passaged inﬂuenza
virus through IFN-resistant cells in order to select for mutants that
were impaired in their ability to prevent IFN induction or signalling.
By this method, a number of mutant viruses were obtained that
were stronger IFN inducers than wild-type virus and several of
these IFN-inducing mutants were found to accumulate large num-
bers of DI genomes in infected cells (Perez-Cidoncha et al., 2014).
We have studied the link between inﬂuenza virus DIs  and IFN
induction in tissue culture and found that a preparation of PR8
virus that has been passaged so as to enrich for DI content is a
much more efﬁcient activator of the IFN response than our start-
ing virus stock, when cells are infected with either an equivalent
amount of total virus particles or plaque-forming virus particles
(Fig. 4). Recent in vivo comparisons of the effects of DI-poor or DI-
rich inﬂuenza virus preparations have shown that the presence of
high numbers of DIs is associated with enhanced IFN- expression
in the lungs of infected mice and a reduction in animal morbidity
(Tapia et al., 2013). Moreover, a preparation of inﬂuenza virus com-
posed of a single DI species generated by reverse genetics (a internal
deletion DI derived from segment 1, Dimmock et al., 2008) pro-
tects mice against infections by heterologous inﬂuenza B virus and
paramyxovirus infections (Easton et al., 2011; Scott et al., 2011).
This protection was  impaired in mice lacking a functional type I
IFN receptor, indicating that this protective effect is mediated at
least in part by activation of the IFN response (Easton et al., 2011;
Scott et al., 2011). What remains unclear is why inﬂuenza virus DI
RNAs should be more effective at inducing IFN than non-defective,
full-length genome segments. Due to the requirements for certain
sequences at each end of the genome segment for packaging into
18 M.J. Killip et al. / Virus Research 209 (2015) 11–22
Fig. 4. DIs in inﬂuenza virus preparations correlate with an enhanced ability to activate the interferon system. DI-preparations of PR8 were obtained by four sequential high
multiplicity passages of the vM0  virus through MDCK cells. The total number of virus particles (haemagglutination units; HAU) and the plaque-forming titre (plaque-forming
units;  PFU) were obtained by haemagglutination assay and plaque assay respectively. A549 cells expressing GFP under the control of an IFN- promoter (A549/pr(IFN-).GFP;
Chen et al., 2010) were infected with the low DI (vM0) or DI-rich (vM4) preparations of PR8 at equivalent infectious titre (0.3 PFU/cell) or an equivalent number of total
virus  particles (1 × 104 HAU/cell). At 16 h post-infection, cells were trypsinised, ﬁxed and analysed by ﬂow cytometry for GFP expression (A). Duplicate monolayers were
harvested for immunoblotting (B); lysates were probed for markers of activation of the interferon system (phospho-IRF3, GFP and MxA), viral NP expression and actin (as a
loading control). The IFN present in culture media was estimated by CPE-reduction bio-assay, and the relative units of IFN (RUI) for each condition are indicated beneath the
immunoblot panels.
virions (Gerber et al., 2014), internal deletion RNAs possess identi-
cal 5′ and 3′ termini to non-defective, full-length genomic RNAs
and would not therefore be expected to differ in their inherent
ability to bind RIG-I. The ability of DI viruses to induce IFN may  sim-
ply be due to a faster replication rate of DI RNAs than full-length
genomes because of their smaller size. Alternatively, DI-mediated
interference with viral polymerase and NP expression may  lead to a
reduction in polymerase-imposed shut-off of cellular gene expres-
sion (Ngunjiri et al., 2012) or affect the efﬁciency of cRNA and vRNA
encapsidation. Furthermore, DI-mediated interference may  reduce
NS1 expression, thereby contributing to IFN induction by limiting
IFN antagonism by the virus. This occurs in DI-rich preparations of
the paramyxovirus parainﬂuenza virus 5, where DIs simultaneously
stimulate the IFN response and interfere with the expression of the
V protein (the viral IFN antagonist) from co-infecting non-defective
virus; as a result, the V protein only accumulates in infected cells
after the IFN induction cascade has already been activated (Killip
et al., 2013). Perhaps smaller segments of genomic RNA, such as
the internal deletion RNAs and NS and M segment RNAs identiﬁed
in RIG-I immunoprecipitates (Baum et al., 2010), form a panhandle
more readily than full-length RNA when they are unencapsidated,
or DI RNPs may  be less stable than full-length RNPs and thus more
prone to releasing free RNA. It is interesting to note that very small
ﬂu genome templates can be replicated in the absence of NP (Resa-
Infante et al., 2010; Turrell et al., 2013); thus, it is a possibility
that small DI RNAs could be replicated without being concurrently
encapsidated and that these unencapsidated replication products
could activate RIG-I.
8. Concluding remarks
Innate immune responses, including the IFNs, play a critical
role in determining the pathogenicity and outcome of an inﬂuenza
virus infection: efﬁcient activation of the IFN system early in infec-
tion effectively restricts viral replication and eliminates the virus,
while excessive activation of innate immune responses actually
increases tissue damage in the host. Here, we have outlined recent
advances in the study of the IFN induction by inﬂuenza viruses and
the identity of the PAMPs produced during inﬂuenza virus infec-
tion; however, several unanswered questions remain. Assuming
the inﬂuenza virus panhandle is recognised by RIG-I during infec-
tion, it is unclear how this RNA structure is able to form in infected
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cells: if the panhandle is formed by free unencapsidated RNA, how
and when in the virus life cycle is this RNA generated? Conversely,
if the panhandle structure can be formed by RNA encapsidated
into RNPs, how are the polymerase and/or NP displaced in order
to expose the genome termini? What are the viral PAMPs that are
generated in conditions when progeny genome synthesis has been
blocked? What are the reasons for the cell-to-cell differences in
activation of the IFN promoter during inﬂuenza virus infections
in vitro and in vivo? Lastly, why are inﬂuenza DIs better able to
induce IFN than non-defective virus? Multiple factors are likely
to inﬂuence IFN induction by inﬂuenza virus during an infection,
including the rate of virus replication, its ability to actively antago-
nise IFN induction, the rate of DI generation by the viral polymerase
and also factors conferred by the host; by gaining a broader com-
prehension of all of these contributing elements, we can more fully
understand the interactions between inﬂuenza virus and the IFN
system and apply this understanding to the development of novel
anti-inﬂuenza therapies.
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